Neoandrographolide
(Synonyms: 新穿心莲内酯; Neoandrographiside) 目录号 : GC36716An anti-inflammatory diterpenoid
Cas No.:27215-14-1
Sample solution is provided at 25 µL, 10mM.
Neoandrographolide is one of the principle diterpenoids isolated from A. paniculata, a well-recognized medicinal plant in Asia. Extracts from A. paniculata have been reported to exert a wide range of therapeutic actions, including immunosuppressant, antithrombotic, anti-inflammatory, antineoplastic, anti-viral, anti-bacterial, anti-diabetic, anti-oxidative stress, antipyretic, anti-edematogenic, and anti-nociceptive activities.1 Neoandrographolide has been shown to inhibit LPS-induced nitric oxide production in inflammatory macrophages after oral administration to mice (25 mg/kg) or by direct addition to cultured macrophages (IC50 = 35.5 ?M).2 At 25 ?M, it can reduce VEGF-induced proliferation of human umbilical vein endothelial cells.3 Neoandrographolide also inhibits the pro-protein convertase furin with an IC50 value of 53.5 ?M.4
1.Jarukamjorn, K., and Nemoto, N.Pharmacological aspects of Andrographis paniculata on health and its major diterpenoid constituent andrographolideJ. Health Sci.54(4)370-381(2008) 2.Batkhuu, J., Hattori, K., Takano, F., et al.Suppression of NO production in activated macrophages in vitro and ex vivo by neoandrographolide isolated from Andrographis paniculataBiol. Pharm. Bull.25(9)1169-1174(2002) 3.Gong, C., Xu, C., Ji, L., et al.A novel semi-synthetic andrographolide analogue A5 inhibits tumor angiogenesis via blocking the VEGFR2-p38/ERK1/2 signal pathwayBiosci. Trends7(5)230-236(2013) 4.Basak, A., Cooper, S., Roberge, A.G., et al.Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl estersBiochem. J.338(Pt 1)107-113(1999)
Cas No. | 27215-14-1 | SDF | |
别名 | 新穿心莲内酯; Neoandrographiside | ||
Canonical SMILES | C[C@@]([C@@H]1CCC2=CCOC2=O)(CCC3)[C@@](CCC1=C)([H])[C@]3(C)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO | ||
分子式 | C26H40O8 | 分子量 | 480.59 |
溶解度 | DMSO: ≥ 250 mg/mL (520.19 mM) | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0808 mL | 10.4039 mL | 20.8078 mL |
5 mM | 0.4162 mL | 2.0808 mL | 4.1616 mL |
10 mM | 0.2081 mL | 1.0404 mL | 2.0808 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet